OncoTherapy Science, Inc. (4564.T)
JPY 25.0
(-4.0%)
JPY 25.0
(-4.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.12 Billion JPY | -1.3% |
| 2022 | -1.1 Billion JPY | 46.1% |
| 2021 | -2.05 Billion JPY | -25.32% |
| 2020 | -1.63 Billion JPY | 25.2% |
| 2019 | -2.18 Billion JPY | 25.87% |
| 2018 | -2.95 Billion JPY | 1.17% |
| 2017 | -2.98 Billion JPY | 0.52% |
| 2016 | -3 Billion JPY | -0.78% |
| 2015 | -2.98 Billion JPY | -51.89% |
| 2014 | -1.96 Billion JPY | 48.16% |
| 2013 | -3.78 Billion JPY | -239.92% |
| 2012 | -1.11 Billion JPY | -194.06% |
| 2011 | 1.18 Billion JPY | 430.24% |
| 2010 | 223.32 Million JPY | -29.92% |
| 2009 | 318.67 Million JPY | 1072.93% |
| 2008 | 27.16 Million JPY | 107.05% |
| 2007 | -385.42 Million JPY | 71.42% |
| 2006 | -1.34 Billion JPY | -61.82% |
| 2005 | -833.44 Million JPY | -2473.08% |
| 2004 | 35.12 Million JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -290 Million JPY | -95.88% |
| 2023 Q3 | -277.99 Million JPY | 9.89% |
| 2023 Q2 | -308.5 Million JPY | 20.13% |
| 2023 Q1 | -386.25 Million JPY | -91.72% |
| 2023 Q4 | -148.04 Million JPY | 46.74% |
| 2023 FY | -1.12 Billion JPY | -1.3% |
| 2022 Q3 | -286.86 Million JPY | 7.68% |
| 2022 Q4 | -201.46 Million JPY | 29.77% |
| 2022 FY | -1.1 Billion JPY | 46.1% |
| 2022 Q2 | -310.72 Million JPY | -1.1% |
| 2022 Q1 | -307.35 Million JPY | 10.22% |
| 2021 Q4 | -342.32 Million JPY | 55.05% |
| 2021 Q3 | -761.55 Million JPY | -101.87% |
| 2021 FY | -2.05 Billion JPY | -25.32% |
| 2021 Q2 | -377.24 Million JPY | 33.99% |
| 2021 Q1 | -571.51 Million JPY | -53.76% |
| 2020 Q3 | -427.64 Million JPY | 2.7% |
| 2020 FY | -1.63 Billion JPY | 25.2% |
| 2020 Q4 | -371.7 Million JPY | 13.08% |
| 2020 Q1 | -399.09 Million JPY | 12.18% |
| 2020 Q2 | -439.5 Million JPY | -10.12% |
| 2019 Q2 | -600.83 Million JPY | 2.75% |
| 2019 Q3 | -516.56 Million JPY | 14.03% |
| 2019 Q1 | -617.83 Million JPY | 23.51% |
| 2019 FY | -2.18 Billion JPY | 25.87% |
| 2019 Q4 | -454.43 Million JPY | 12.03% |
| 2018 Q2 | -1.01 Billion JPY | -42.1% |
| 2018 FY | -2.95 Billion JPY | 1.17% |
| 2018 Q4 | -807.74 Million JPY | -92.25% |
| 2018 Q1 | -712.87 Million JPY | 7.57% |
| 2018 Q3 | -420.15 Million JPY | 58.52% |
| 2017 Q1 | -593.17 Million JPY | 26.66% |
| 2017 FY | -2.98 Billion JPY | 0.52% |
| 2017 Q4 | -771.29 Million JPY | 2.57% |
| 2017 Q3 | -791.66 Million JPY | 4.9% |
| 2017 Q2 | -832.47 Million JPY | -40.34% |
| 2016 FY | -3 Billion JPY | -0.78% |
| 2016 Q2 | -736.42 Million JPY | 6.0% |
| 2016 Q4 | -808.78 Million JPY | -19.72% |
| 2016 Q3 | -675.58 Million JPY | 8.26% |
| 2016 Q1 | -783.43 Million JPY | -10.17% |
| 2015 Q4 | -711.13 Million JPY | 10.64% |
| 2015 FY | -2.98 Billion JPY | -51.89% |
| 2015 Q1 | -672.25 Million JPY | -88.29% |
| 2015 Q2 | -801.67 Million JPY | -19.25% |
| 2015 Q3 | -795.84 Million JPY | 0.73% |
| 2014 Q1 | -333.56 Million JPY | 57.7% |
| 2014 FY | -1.96 Billion JPY | 48.16% |
| 2014 Q2 | -747.22 Million JPY | -124.01% |
| 2014 Q3 | -524.65 Million JPY | 29.79% |
| 2014 Q4 | -357.03 Million JPY | 31.95% |
| 2013 Q1 | -1.06 Billion JPY | -325.44% |
| 2013 Q3 | -912.28 Million JPY | 10.57% |
| 2013 FY | -3.78 Billion JPY | -239.92% |
| 2013 Q4 | -788.64 Million JPY | 13.55% |
| 2013 Q2 | -1.02 Billion JPY | 4.2% |
| 2012 Q2 | -383.63 Million JPY | 48.27% |
| 2012 Q1 | -741.55 Million JPY | -122.26% |
| 2012 FY | -1.11 Billion JPY | -194.06% |
| 2012 Q3 | -460.89 Million JPY | -20.14% |
| 2012 Q4 | 472.33 Million JPY | 202.48% |
| 2011 Q4 | 3.33 Billion JPY | 633.47% |
| 2011 Q1 | -1.01 Billion JPY | -722.22% |
| 2011 Q2 | -504.19 Million JPY | 50.5% |
| 2011 Q3 | -624.47 Million JPY | -23.86% |
| 2011 FY | 1.18 Billion JPY | 430.24% |
| 2010 Q1 | -799.2 Million JPY | -157.33% |
| 2010 Q2 | 302.57 Million JPY | 137.86% |
| 2010 Q3 | 556.24 Million JPY | 83.84% |
| 2010 Q4 | 163.7 Million JPY | -70.57% |
| 2010 FY | 223.32 Million JPY | -29.92% |
| 2009 Q1 | -767.59 Million JPY | -141.85% |
| 2009 FY | 318.67 Million JPY | 1072.93% |
| 2009 Q4 | 1.39 Billion JPY | 750.89% |
| 2009 Q3 | 163.84 Million JPY | 134.73% |
| 2009 Q2 | -471.71 Million JPY | 38.55% |
| 2008 FY | 27.16 Million JPY | 107.05% |
| 2008 Q3 | -518.96 Million JPY | 0.0% |
| 2008 Q4 | 1.83 Billion JPY | 453.44% |
| 2007 FY | -385.42 Million JPY | 71.42% |
| 2006 FY | -1.34 Billion JPY | -61.82% |
| 2005 FY | -833.44 Million JPY | -2473.08% |
| 2004 FY | 35.12 Million JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 596.82 Million JPY | 287.795% |
| PRISM BioLab Co.,LTD | -496.86 Million JPY | -125.573% |
| GNI Group Ltd. | 13.1 Billion JPY | 108.55% |
| Linical Co., Ltd. | 725.72 Million JPY | 254.439% |
| Trans Genic Inc. | 89.43 Million JPY | 1353.186% |
| MEDINET Co., Ltd. | -1.42 Billion JPY | 21.4% |
| Soiken Holdings Inc. | -610 Million JPY | -83.735% |
| Cytori Cell Research Institute, Inc. | -772.74 Million JPY | -45.042% |
| AnGes, Inc. | -11.96 Billion JPY | 90.635% |
| Nxera Pharma Co., Ltd. | -9.52 Billion JPY | 88.234% |
| Immuno-Biological Laboratories Co., Ltd. | 104.29 Million JPY | 1174.602% |
| NanoCarrier Co., Ltd. | -864.41 Million JPY | -29.66% |
| Carna Biosciences, Inc. | -1.11 Billion JPY | -0.342% |
| CanBas Co., Ltd. | -1.26 Billion JPY | 11.189% |
| D. Western Therapeutics Institute, Inc. | -798.55 Million JPY | -40.353% |
| RaQualia Pharma Inc. | -337.36 Million JPY | -232.221% |
| Chiome Bioscience Inc. | -1.2 Billion JPY | 7.001% |
| Kidswell Bio Corporation | -1.33 Billion JPY | 16.083% |
| PeptiDream Inc. | 6.77 Billion JPY | 116.548% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 41.927% |
| Ribomic Inc. | -1.11 Billion JPY | -0.413% |
| SanBio Company Limited | -4.53 Billion JPY | 75.307% |
| Healios K.K. | -3.37 Billion JPY | 66.83% |
| BrightPath Biotherapeutics Co., Ltd. | -1.15 Billion JPY | 2.968% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 19.57% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 20.114% |
| StemRIM | -2.07 Billion JPY | 46.012% |
| CellSource Co., Ltd. | 1.22 Billion JPY | 191.756% |
| FunPep Company Limited | -994 Million JPY | -12.756% |
| Kringle Pharma, Inc. | -888.76 Million JPY | -26.108% |
| Stella Pharma Corporation | -760.3 Million JPY | -47.415% |
| TMS Co., Ltd. | -943.25 Million JPY | -18.823% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | -44.546% |
| Cuorips Inc. | -588.48 Million JPY | -90.454% |
| K Pharma,Inc. | 366.05 Million JPY | 406.182% |
| Takara Bio Inc. | 3 Billion JPY | 137.323% |
| ReproCELL Incorporated | -409.29 Million JPY | -173.838% |
| PhoenixBio Co., Ltd. | 11.06 Million JPY | 10231.058% |
| StemCell Institute Inc. | 413.75 Million JPY | 370.882% |
| Japan Tissue Engineering Co., Ltd. | 144.5 Million JPY | 875.602% |
| CellSeed Inc. | -697.77 Million JPY | -60.624% |